195. ヌーナン症候群 Noonan syndrome Clinical trials / Disease details
臨床試験数 : 14 / 薬物数 : 15 - (DrugBank : 5) / 標的遺伝子数 : 2 - 標的パスウェイ数 : 9
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03435627 (ClinicalTrials.gov) | February 26, 2018 | 31/1/2018 | Post Marketing Surveillance on Long-term Use With Norditropin® (Short Stature Due to Noonan Syndrome) | Post Marketing Surveillance on Long-term Use With Norditropin® (Short Stature Due to Noonan Syndrome) | Genetic Disorder;Noonan Syndrome | Drug: Somatropin | Novo Nordisk A/S | NULL | Completed | 3 Years | N/A | All | 71 | Japan | |
| 2 | NCT01927861 (ClinicalTrials.gov) | August 19, 2013 | 20/8/2013 | Investigating the Long-term Efficacy and Safety of Two Doses of NN-220 (Somatropin) in Short Stature Due to Noonan Syndrome | A 52-week, Multi-centre, Randomised, Double-blind, Parallel-group, no Treatment Controlled (Open-label) Trial Investigating the Efficacy and Safety of Two Doses of NN-220 in Short Stature With Noonan Syndrome | Genetic Disorder;Noonan Syndrome | Drug: somatropin | Novo Nordisk A/S | NULL | Completed | 3 Years | 10 Years | All | 51 | Phase 3 | Japan |
| 3 | NCT01529944 (ClinicalTrials.gov) | September 2008 | 2/1/2012 | Genetic Testing of Noonan Subjects Previously Treated With Norditropin®. An Extension to Trial GHNOO-1658 | Genetic Testing of Noonan Subjects Previously Treated With Norditropin® in the GHNOO-1658 Trial | Genetic Disorder;Noonan Syndrome | Drug: somatropin | Novo Nordisk A/S | NULL | Completed | N/A | N/A | Both | 22 | Phase 3 | Sweden |
| 4 | NCT00960128 (ClinicalTrials.gov) | April 1, 2006 | 13/8/2009 | Observational Prospective Study on Patients Treated With Norditropin® | NordiNet® International Outcome Study-Observational Prospective Study on Patients Treated With Norditropin® | Growth Hormone Disorder;Growth Hormone Deficiency in Children;Adult Growth Hormone Deficiency;Genetic Disorder;Turner Syndrome;Foetal Growth Problem;Small for Gestational Age;Chronic Kidney Disease;Chronic Renal Insufficiency;Noonan Syndrome | Drug: somatropin | Novo Nordisk A/S | NULL | Completed | N/A | N/A | All | 21249 | N/A | Argentina;Belgium;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Israel;Italy;Lithuania;Luxembourg;Netherlands;Norway;Russian Federation;Saudi Arabia;Serbia;Slovenia;Spain;Sweden;Switzerland;United Kingdom;Brazil;Czech Republic;Former Serbia and Montenegro |
| 5 | EUCTR2005-000042-37-SE (EUCTR) | 11/07/2005 | 12/04/2005 | Norditropin Treatment in Subjects with Noonan Syndrome. Effects on Linear Growth and Final Height - Data Collection and Follow-up Visit | Norditropin Treatment in Subjects with Noonan Syndrome. Effects on Linear Growth and Final Height - Data Collection and Follow-up Visit | Noonan syndrome associated short stature MedDRA version: 7.1;Level: PT;Classification code 10029748 | Trade Name: Norditropin 24 IU Product Name: Norditropin 24 IU INN or Proposed INN: Somatropin Trade Name: Norditropin SimpleXx Product Name: Norditropin SimpleXx INN or Proposed INN: Somatropin INN or Proposed INN: Somatropin INN or Proposed INN: Somatropin | Novo Nordisk A/S | NULL | Not Recruiting | Female: yes Male: yes | Sweden | ||||
| 6 | NCT00452725 (ClinicalTrials.gov) | October 1997 | 23/3/2007 | Effect of MAXOMAT ® on the Growth of Small Children to NOONAN's Syndrome | Effect of the Growth Hormone MAXOMAT ® on the Growth of Small Children and Adolescents (<-2 SD) Due to NOONAN's Syndrome | Noonan Syndrome | Drug: MAXOMAT ®, biosynthetic growth hormone | Sanofi | NULL | Completed | 3 Years | 15 Years | Both | 36 | Phase 3 | France |
| 7 | NCT01529840 (ClinicalTrials.gov) | June 1990 | 2/1/2012 | Somatropin Effect on Linear Growth and Final Height in Subjects With Noonan Syndrome | Norditropin Treatment in Subjects With Noonan Syndrome. Effects on Linear Growth and Final Height - Data Collection and Follow-up Visit | Genetic Disorder;Noonan Syndrome | Drug: somatropin | Novo Nordisk A/S | NULL | Completed | 18 Years | N/A | All | 24 | Phase 3 | Sweden |